About PathoQuest
PathoQuest is a Healthcare company based in Paris (France) founded in 2010, and was acquired by Charles River Laboratories in January 2026. Next-generation sequencing is provided for microbiology testing applications. PathoQuest has raised $9.99 million across 4 funding rounds from investors including Charles River Laboratories, Eurazeo and Idinvest Partners. PathoQuest offers products and services including iDTECT Platform, Adventitious Virus Testing, Cell Line Characterization, and Raw Material Testing. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Microbial Testing.
Company details
PathoQuest was founded in 2010 and is based in Paris, France. Operations focus on the biotechnology sector, where next-generation sequencing is integrated with sample preparation, cloud-based bioinformatics, and a pathogen genome database for automated analysis. Services support quality control in biologicals and infection diagnosis through these combined technologies.
- Headquarters Paris, France
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website pathoquest.com
- Acquired by Charles River Laboratories (Jan 2026)
- Total Equity Funding$9.99M (USD)
in 4 rounds
- InvestorsCharles River Laboratories
& 9 more
- Acquired byCharles River Laboratories
(Jan 2026)
Products & Services of PathoQuest
PathoQuest offers a comprehensive portfolio of products and services, including iDTECT Platform, Adventitious Virus Testing, Cell Line Characterization, and Raw Material Testing.
Platform for viral safety and genetic characterization of biopharmaceuticals
Detects viral contamination in manufacturing processes
Screens and tests manufacturing cells for stability
Screens high-risk inputs for potential contaminants
Funding Insights of PathoQuest
PathoQuest has successfully raised a total of $9.99M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.99M
- Total Rounds 4
- First Round $4.96M
(Jul 2013)
- Investors Count 10
All 4 funding rounds of PathoQuest with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | Series B | – | SHS | ||
| Sep 2019 | $5.03M | Series B | – | Kurma Partners, Charles River Laboratories | |
| Sep 2019 | $3.77M | Debt – Venture | – | – | |
| Jul 2013 | $4.96M | Series B | – | – |
10 investors in total: 10 institutional.
Investors in PathoQuest
PathoQuest has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Charles River Laboratories, Eurazeo and Idinvest Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare-focused private equity investments are managed by SHS Capital. | 1993 | shs-capital.eu | Tübingen, Germany | |
Private equity investments are made in companies across diverse sectors. | turennecapital.com | Paris, France | ||
Biotech startups are funded through venture capital in life sciences. | 2009 | kurmapartners.com | Paris, France | |
Venture capital firm focused on science and tech-driven startups | verve.vc | Berlin, Germany | ||
Private equity and debt investments are managed across multiple sectors. | 1969 | eurazeo.com | Paris, France | |
| aurinvest.com | ||||
Equity investments are provided to low and middle market companies. | 1997 | idinvest.com | Paris, France | |
| norgineventures.com | ||||
Provider of drug discovery and preclinical development services | 1947 | criver.com | Wilmington, United States | |
| gouvernement.fr |
Investor details for PathoQuest
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PathoQuest
17 people are tracked at PathoQuest (8 in leadership, 1 in board & advisors, 8 in team).
| Name | Role | Group |
|---|---|---|
Jean-François Brepson | President & CEO | Leadership |
Violaine Mélen | Chief of Quality Assurance & Regulatory Affairs Officer/ Qualified Person | Leadership |
Eric Cazergue | CFO | Leadership |
Sébastien Renouf | Chief Pharmaceutical Officer | Leadership |
Colette Cote | Chief Portfolio Officer and General Manager, US Operations | Leadership |
Christine Dangles | Chief HR & Facilities Officer | Leadership |
Guillaume Deplaine | COO | Leadership |
Quynh Ton, Ph.D | Regional Sales Director: Next Generation Sequencing Application Specialist | Leadership |
Benedikt von Braunmühl | Chairman of the Board of Directors | Board & advisors |
Emeline Sarry | Responsable Contrôle Qualité | Team |
Meissa Barbouche | Engineer of industrial affairs department at PathoQuest | Team |
Carmela Cataudella-Sanzone | Human Resources and Office Manager | Team |
Céline DUPONT | Technicienne Supérieure Operations | Team |
Amina CHERIF LOUAZANI | Viral Safety And Regulatory Affairs Manager | Team |
Camille Novo | Responsable AQ Opérationnelle Support Analytique | Team |
Yoann Lecat | Responsable Ressources Humaines | Team |
Kimberley Ramsey | Business Development Manager | Team |
Complete people profiles for PathoQuest
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PathoQuest
4 dated milestones of PathoQuest across 16 years, from founding to its latest funding, stage changes and deals.
- Founded PathoQuest is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series B,.
- Exit Acquired by Charles River Laboratories.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pathoquest
Complete news archive for PathoQuest
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PathoQuest
PathoQuest was founded in 2010 and raised its 1st funding round 3 years after it was founded.
PathoQuest is headquartered in Paris, France.
PathoQuest is a funded company, having raised a total of $9.99M across 4 funding rounds to date. The company's 1st funding round was a Series B of $4.96M, raised on Jul 2013.
PathoQuest was founded in 2010 and is based in Paris, France. Operations focus on the biotechnology sector, where next-generation sequencing is integrated with sample preparation, cloud-based bioinformatics, and a pathogen genome database for automated analysis. Services support quality control in biologicals and infection diagnosis through these combined technologies.
PathoQuest offers iDTECT Platform, Adventitious Virus Testing, Cell Line Characterization, and Raw Material Testing.
PathoQuest has 10 investors. Key investors include Charles River Laboratories, Eurazeo, Idinvest Partners, Kurma Partners, and SHS Capital.
Yes. PathoQuest was acquired by Charles River Laboratories in January 2026.